AVIR Stock Forecast: Atea Pharmaceuticals, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering Atea Pharmaceuticals, Inc. hold a median 12-month price target of $9 — +127.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 81 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Atea Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (93): The share price has been relatively steady.
Growth (19): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
AVIR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AVIR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +127.3% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Nov 2026 | Morgan Stanley | Maintains | Equal-Weight | $7.00 → $8.00 |
| 13 Aug 2026 | Morgan Stanley | Maintains | Equal-Weight | $6.00 → $7.00 |
| 9 Mar 2026 | Evercore ISI Group | Maintains | Outperform | $6.00 → $10 |
| 11 Apr 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 13 Aug 2024 | Morgan Stanley | Upgrade | Equal-Weight | — |
| 10 Aug 2023 | JP Morgan | Downgrade | Underweight | — |
| 16 Mar 2023 | JP Morgan | Maintains | Neutral | — |
| 27 Jan 2023 | SVB Leerink | Maintains | Market Perform | — |
| 24 Jan 2023 | Morgan Stanley | Maintains | Underweight | — |
| 15 Aug 2022 | Morgan Stanley | Maintains | Underweight | — |
| 2 Mar 2022 | JP Morgan | Maintains | Neutral | — |
| 1 Mar 2022 | SVB Leerink | Maintains | Market Perform | — |
| 16 Feb 2022 | SVB Leerink | Maintains | Market Perform | — |
| 6 Jan 2022 | Morgan Stanley | Downgrade | Underweight | — |
| 18 Nov 2021 | SVB Leerink | Downgrade | Market Perform | — |
| 20 Oct 2021 | JP Morgan | Downgrade | Neutral | — |
| 20 Oct 2021 | SVB Leerink | Maintains | Outperform | — |
| 5 Oct 2021 | Morgan Stanley | Downgrade | Equal-Weight | — |
| 9 Sept 2021 | SVB Leerink | Initiates | Outperform | — |
| 18 Aug 2021 | Morgan Stanley | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for AVIR.
This page is one stock. Monday covers all of them.
AVIR appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
AVIR vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Atea Pharmaceuticals, Inc. returned +32.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
AVIR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 1.8×
- EV / EBITDA
- —
Cheaper than 47% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −63.2%
- Return on assets
- −39.5%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Atea Pharmaceuticals, Inc. has a market value of $315.6M and an enterprise value of $124.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$165.3M.
Diluted earnings per share, trailing twelve months: −$2.08.
Free cash flow in the twelve months to 30 June 2026: −$152.1M.
Atea Pharmaceuticals, Inc. spent $11.4M on share buybacks in the twelve months to 30 June 2026.
Atea Pharmaceuticals, Inc. employs 55 people.
Data provided by Twelve Data
AVIR and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at AVIR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Atea Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about AVIR
What is the AVIR stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Atea Pharmaceuticals, Inc. have a median 12-month price target of $9, with estimates ranging from $8 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AVIR stock a buy right now?
Of the 3 analysts covering Atea Pharmaceuticals, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Atea Pharmaceuticals, Inc. 81 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AVIR?
As at 21 Nov 2026, Atea Pharmaceuticals, Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (93 of 100).
Will AVIR stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +127.3% from the last close, and Ticker Nerd's factor model ranks Atea Pharmaceuticals, Inc. 81 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AVIR stock forecast for 2030?
No analyst covering Atea Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVIR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $10 over the next 12 months.
How has AVIR stock performed over the past year?
Atea Pharmaceuticals, Inc. returned +32.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Atea Pharmaceuticals, Inc. do?
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapies for serious viral infections. Atea Pharmaceuticals’ current programs center on treatments for hepatitis C, including a late-stage regimen combining bemnifosbuvir and ruzasvir, as well as broader antiviral research across other RNA virus targets.
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapies for serious viral infections. Atea Pharmaceuticals’ current programs center on treatments for hepatitis C, including a late-stage regimen combining bemnifosbuvir and ruzasvir, as well as broader antiviral research across other RNA virus targets. The company also works on therapies for hepatitis E and other viral diseases, reflecting its emphasis on unmet medical needs in infectious disease. Its portfolio is designed around small-molecule oral medicines, which are intended to support convenient outpatient treatment options and address diseases that can require long-term or difficult-to-administer care. Based in Boston, Massachusetts, Atea Pharmaceuticals operates in the biopharmaceutical sector, where antiviral drug development plays a significant role in advancing treatment choices for patients and healthcare providers.
CEO Dr. Jean-Pierre Sommadossi Ph.D. · 55 employees · United States · https://ateapharma.com